HHS Public Access Author manuscript Author Manuscript

Clin Endocrinol (Oxf). Author manuscript; available in PMC 2017 November 01. Published in final edited form as: Clin Endocrinol (Oxf). 2016 November ; 85(5): 772–780. doi:10.1111/cen.13130.

Effect of Testosterone on Hepcidin, Ferroportin, Ferritin and Iron Binding Capacity in Patients with Hypogonadotropic Hypogonadism and Type 2 Diabetes

Author Manuscript

SANDEEP DHINDSA1,2, HUSAM GHANIM1, MANAV BATRA1, NITESH D. KUHADIYA1, SANAA ABUAYSHEH1, KELLY GREEN1, ANTOINE MAKDISSI1, AJAY CHAUDHURI1, and PARESH DANDONA1 1Division

of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, 462 Grider St, Buffalo, NY 14215

2Division

of Endocrinology, Diabetes and Metabolism, Texas Tech University Health Sciences Center, 701 w 5th street, Odessa, TX-79763

Abstract Context—Since the syndrome of hypogonadotropic hypogonadism (HH) is associated with anemia and the administration of testosterone restores hematocrit to normal, we investigated the potential underlying mechanisms. Design—Randomized, double blind, placebo controlled trial

Author Manuscript

Methods—We measured basal serum concentrations of erythropoietin, iron, iron binding capacity, transferrin (saturated and unsaturated), ferritin and hepcidin and the expression of ferroportin and transferrin receptor (TR) in peripheral blood mononuclear cells (MNC) of 94 men with type 2 diabetes. 44 men had HH (defined as subnormal free testosterone along with low or normal LH concentrations) while 50 were eugonadal. Men with HH were randomized to testosterone or placebo treatment every 2 weeks for 15 weeks. Blood samples were collected at

Author Manuscript

Correspondence To: Paresh Dandona, B.Sc., M.B. B.S., D.Phil., F.R.C.P., Director, Diabetes-Endocrinology Center of Western NY, Chief of Endocrinology, State University of New York at Buffalo, 462 Grider St, Buffalo, NY 14215, Phone: 716-898-1940, Fax: 716-898-1952, [email protected]. CONFLICTS OF INTEREST: SD: Abbvie (speaker panel and research support) HG: none MB: none NK: Novo Nordisk (speaker panel) SA: none KG: none AM: none AC: Eli Lilly, Sanofi-Avenits (speaker panel) PD: Research Support: GlaxoSmithKline; Novo Nordisk; Bristol Meyer Squibb; Takeda Pharmaceuticals; Allergan; Sanofi-Aventis; Conjuchem; Dannipon Pharmaceuticals; Proctor and Gamble Pharma; Mitsubishi; Quigley Pharma Inc.; Solvay Pharmaceuticals; Transition Therapeutics; ToleRx Honorarium: Eli Lilly; Novartis; GlaxoSmithKline; Merck; Novo Nordisk; Takeda; Sanofi-Aventis Grants: National Institutes of Health; GlaxoSmithKline; Center for Disease Control; Bristol Meyers Squibb; Novartis Pharmaceuticals; Abbott Labs; Takeda Pharmaceuticals; Sankyo Pharmaceuticals North America; Oishei Foundation; Citrus Industry of Florida; Solvay Pharmaceuticals; William G. McGowan Charitable Fund; Millard Fillmore Foundation

DHINDSA et al.

Page 2

Author Manuscript

baseline, 3 and 15 weeks after starting treatment. 20 men in testosterone group and 14 men in placebo group completed the study. Results—Hematocrit levels were lower in men with HH (41.1±3.9% vs. 43.8±3.4%, p=0.001). There were no differences in plasma concentrations of hepcidin, ferritin, erythropoietin, transferrin or iron, or in the expression of ferroportin or TR in MNC among HH and eugonadal men. Hematocrit increased to 45.3±4.5%, hepcidin decreased by 28±7% and erythropoietin increased by 21±7% after testosterone therapy (p

Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes.

As the syndrome of hypogonadotropic hypogonadism (HH) is associated with anaemia and the administration of testosterone restores haematocrit to normal...
573KB Sizes 0 Downloads 10 Views